Humanized anti-CD137 mAb is in Phase II clinical trials to treat melanoma patients, and its use is being evaluated in treating autoimmune and other inflammatory diseases and as adjuvants for vaccines. The gene discussed is TNFRSF9; the disease is melanoma.